Published April 3, 2022 | Version v1
Journal article Open

Comparative Proteomic Profiling of Secreted Extracellular Vesicles from Breast Fibroadenoma and Malignant Lesions: A Pilot Study

Authors/Creators

  • 1. IRCCS SYNLAB SDN
  • 2. National Research Council
  • 3. Federico II University of Naples
  • 4. Percuros BV
  • 5. Mediterranea Cardiocentro
  • 6. University of Ottawa
  • 7. ederico II University of Naples

Description

Extracellular vesicles (EVs) shuttle proteins, RNA, DNA, and lipids crucial for cell-to-cell communication. Recent findings have highlighted that EVs, by virtue of their cargo, may also contribute to breast cancer (BC) growth and metastatic dissemination. Indeed, EVs are gaining great interest as non-invasive cancer biomarkers. However, little is known about the biological and physical properties of EVs from malignant BC lesions, and even less is understood about EVs from non-malignant lesions, such as breast fibroadenoma (FAD), which are clinically managed using conservative approaches. Thus, for this pilot study, we attempted to purify and explore the proteomic profiles of EVs from benign breast lesions, HER2+ BCs, triple–negative BCs (TNBCs), and continuous BC cell lines (i.e., BT-549, MCF–10A, and MDA-MB-231), combining experimental and semi-quantitative approaches. Of note, proteome-wide analyses showed 49 common proteins across EVs harvested from FAD, HER2+ BCs, TNBCs, and model BC lines. This is the first feasibility study evaluating the physicochemical composition and proteome of EVs from benign breast cells and primary and immortalized BC cells. Our preliminary results hold promise for possible implications in precision medicine for BC.

Notes

"This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 891551".

Files

Comparative Proteomic Profiling of Secreted Extracellular.pdf

Files (6.6 MB)

Additional details

Funding

European Commission
PRISAR2 - proactive monitoring of cancer as an alternative to surgery 872860
European Commission
PAVE - A nanovaccine Approach for the treatment of Pancreatic Cancer 861190
European Commission
CONCRETE - Concept Creation Technology 611733
European Commission
BARRICADE - evolutionary platform to predict breast cancer (BC) patients outcome and response to therapy 895151
European Commission
Gl.EXO - Innovative tools to detect Glioblastoma (GBM) exosomes 891551